Figure S4. Chemotherapy dose titration in NSG mice engrafted with KG1a. NSG mice were engrafted with KG1a and a range of chemotherapy doses were tested (n = 3/group). We determined a dose (8 mg/kg AraC + 0.24 mg/kg DNR) that would moderately reduce KG1a engraftment in the bone marrow, determined by flow cytometry analysis (described in Methods), while remaining well below the maximum tolerated dose, as determined by Wunderlich et al. [22]. (TIF 188 kb
Multidrug-resistance phenotype of murine MDR1 gene-modified 32D cells. 32D cells transduced with LV....
Figure S8. The anti-leukaemic effects of CKI on B-NSG mice with Molm-13 GFP+ cell injections. (A) A ...
Dose response curve and chemoprotection of leukemia cells by MSC. a-c Dose response curve showing pe...
Figure S5. Gating strategy for in vivo bone marrow samples. Bone marrows were harvested from KG1a-en...
Figure S1. Gating strategy for 2 h flow-based cytotoxicity assay. Target cells were stained with PKH...
Figure S2. Calculation of % specific killing by DNTs post-chemotherapy treatment in vitro. This sche...
Table S1. Percentages of dead AML3 and KG1a cells after chemotherapy and DNT co-culture. This table ...
Figure S7. Determination of single dose maximum tolerated dose (MTD). (A) Nu/Nu nude mice were treat...
(A/B) Ba/F3 vector cells and cells transformed with pBABE Bcr-Abl were exposed to the indicated inhi...
Table S2. Clinical characteristics of 13 AML patients whose AML blasts were used for in vitro assays...
Figure S1. The combination effect of MPT0G211 and chemotherapeutic agent on acute leukemia cell line...
Figure S3. In vivo efficacy profile of TEG001 in PD-X model of primary blast in NSG-SGM3 mice. (A) S...
Figure S1. a Cancer-associated fibroblasts (CAFs) culture-conditioned media used with MKN-45 and MKN...
Figure S1. (A) Scheme of the synthesis of PBAE 447. (B) 1 H NMR spectra of PBAE 447 polymer in DMSO-...
Figure S2. Gating strategy for flow cytometry analysis of primary AML burden. A representative flow ...
Multidrug-resistance phenotype of murine MDR1 gene-modified 32D cells. 32D cells transduced with LV....
Figure S8. The anti-leukaemic effects of CKI on B-NSG mice with Molm-13 GFP+ cell injections. (A) A ...
Dose response curve and chemoprotection of leukemia cells by MSC. a-c Dose response curve showing pe...
Figure S5. Gating strategy for in vivo bone marrow samples. Bone marrows were harvested from KG1a-en...
Figure S1. Gating strategy for 2 h flow-based cytotoxicity assay. Target cells were stained with PKH...
Figure S2. Calculation of % specific killing by DNTs post-chemotherapy treatment in vitro. This sche...
Table S1. Percentages of dead AML3 and KG1a cells after chemotherapy and DNT co-culture. This table ...
Figure S7. Determination of single dose maximum tolerated dose (MTD). (A) Nu/Nu nude mice were treat...
(A/B) Ba/F3 vector cells and cells transformed with pBABE Bcr-Abl were exposed to the indicated inhi...
Table S2. Clinical characteristics of 13 AML patients whose AML blasts were used for in vitro assays...
Figure S1. The combination effect of MPT0G211 and chemotherapeutic agent on acute leukemia cell line...
Figure S3. In vivo efficacy profile of TEG001 in PD-X model of primary blast in NSG-SGM3 mice. (A) S...
Figure S1. a Cancer-associated fibroblasts (CAFs) culture-conditioned media used with MKN-45 and MKN...
Figure S1. (A) Scheme of the synthesis of PBAE 447. (B) 1 H NMR spectra of PBAE 447 polymer in DMSO-...
Figure S2. Gating strategy for flow cytometry analysis of primary AML burden. A representative flow ...
Multidrug-resistance phenotype of murine MDR1 gene-modified 32D cells. 32D cells transduced with LV....
Figure S8. The anti-leukaemic effects of CKI on B-NSG mice with Molm-13 GFP+ cell injections. (A) A ...
Dose response curve and chemoprotection of leukemia cells by MSC. a-c Dose response curve showing pe...